Lannett ships Morphine Sulfate Oral Solution
The supplying of the product follows approval from the US Food and Drug Administration (FDA) its 505(b)(2) new drug application (NDA). Lannett president and CEO Arthur Bedrosian said
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.